Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
- Written by PR Newswire
- Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3
- MSA is a rare, rapidly progressing, neurodegenerative disease with no approved treatments available4,5
- The innovative...
